US › Healthcare

OmniAb Inc. (OABI)

US · Healthcare · Biotechnology

$2.00+2.04%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$14.4M
Revenue YoY
+246.7%
Net profit
$-7.7M
Profit YoY
+57.7%
EPS
$-0.06
EPS estimate
$-0.10
Net margin
-53.5%

EPS came in at -0.06 against a street estimate of -0.10 — a beat of 40.0%.

Key statistics

Market cap
$284.1M
Forward P/E
0.0
P/B
1.10
Book value
$1.81
EPS (TTM)
$-0.46
52-week high
$2.79
52-week low
$1.30
50-day MA
$2.31
200-day MA
$1.88
Beta
1.22

Analyst view

Analysts rate OmniAb Inc. a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $7.33.

Shareholding

Insiders
15.33%
Institutions
51.12%

Largest institutional holders

FundStake
Whitefort Capital Management, LP.9.81%
BlackRock Inc5.59%
Cadian Capital Management LP2.87%
Vanguard Capital Management, LLC2.75%
Geode Capital Management, LLC2.02%
Rice Hall James & Associates, LLC1.76%
Private Management Group Inc1.68%
State Street Corp1.43%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for OmniAb Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.